Flyer

International Journal of Drug Development and Research

  • ISSN: 0975-9344
  • Journal h-index: 38
  • Journal CiteScore: 46.78
  • Journal Impact Factor: 1.95
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
20+ Million Readerbase
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Publons
  • MIAR
  • University Grants Commission
  • Euro Pub
  • Google Scholar
  • Secret Search Engine Labs
  • ResearchGate
Share This Page

Rational use of oral lipid-based systems in the development and life cycle management of poor water soluble drugs: Biopharmaceutical considerations and case studies

17th Edition of International Conference and Exhibition on Pharmaceutics and Novel Drug Delivery Systems
October 04-06, 2018 Moscow, Russia

Panayiotis P Constantinides

Biopharmaceutical & Drug Delivery Consulting, USA

Posters & Accepted Abstracts: Int J Drug Dev & Res

Abstract:

Lipid-based systems are widely used in drug development and life cycle management to enhance the solubility, dissolution and oral bioavailability of poor water soluble drugs (BCS II and IV) with several drug products on the market. Despite the progress, however, a pharmaceutical formulator is often contemplating with a number of questions: a) why to consider lipid-based systems over other approaches? b) When lipid excipients and formulations can be applied based on the physicochemical properties of the drug substance? c) What specific lipid formulations and dosage forms to use for expeditious proof of concept studies? This presentation will address these questions and discuss best practices in the pharmaceutical industry. Physicochemical characteristics of lipid excipients and formulations along with a biopharmaceutical rationale for their use with poorly soluble drugs will be presented during the first part of the talk. Specific dosage forms, such as, liquid filled hard and soft gelatin capsules, as well as solid dosage forms (tablets and capsules) incorporating lipid formulations will be addressed during the second part of the presentation and compared against certain desired product development characteristics. Then, case studies with BCS II and IV drugs, will highlight biopharmaceutical benefits using lipid formulations which include, improved pharmacokinetics, promotion of lymphatic absorption and inhibition of intestinal metabolism and efflux pumps. The talk will conclude with lessons learned and future perspectives in the field.

Biography :

E-mail:

[email protected]